Obstructive Lung Disease
10
0
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Secondhand Smoke Respiratory Health Study
Pulmonary Outcomes of Bronchopulmonary Dysplasia in Young Adulthood
Optimized Single-breath Helium Lung Volume in Obstructive Lung Disease
Determinants of COVID-19 Pneumonia (MC-19)
Prognostic Factors Keeping Track for COVID-19 Pneumonia
Breathing and Bones Initiative
Probiotic Use in Patients With Prior COPD Exacerbation
Inhalation Therapy in Ambulant and Hospitalized Patient Using Available Film Sequences From the Internet
Airway Inflammation Among Workers in the Silicon Carbide Processing Industry
Treatment With AKL1 in Obstructive Airways Disease (The TAKL Study)